Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2017 Jan 10;35(2):139-140.
doi: 10.1200/JCO.2016.70.4692. Epub 2016 Nov 28.

Reaffirming and Clarifying the American Society of Clinical Oncology's Policy Statement on the Critical Role of Phase I Trials in Cancer Research and Treatment

Jeffrey S Weber  1 , Laura A Levit  1 , Peter C Adamson  1 , Suanna S Bruinooge  1 , Howard A Burris 3rd  1 , Michael A Carducci  1 , Adam P Dicker  1 , Mithat Gönen  1 , Stephen M Keefe  1 , Michael A Postow  1 , Michael A Thompson  1 , David M Waterhouse  1 , Susan L Weiner  1 , Lynn M Schuchter  1
Affiliations
Comment

Reaffirming and Clarifying the American Society of Clinical Oncology's Policy Statement on the Critical Role of Phase I Trials in Cancer Research and Treatment

Jeffrey S Weber et al. J Clin Oncol. .

Erratum in

  • Errata.
    [No authors listed] [No authors listed] J Clin Oncol. 2019 Feb 1;37(4):357. doi: 10.1200/JCO.18.02273. J Clin Oncol. 2019. PMID: 30695666 Free PMC article. No abstract available.
No abstract available

PubMed Disclaimer

Comment on

References

    1. Kimmelman J. Is participation in cancer phase I trials really therapeutic? J Clin Oncol. doi: 10.1200/JCO.2016.67.9902. - DOI - PMC - PubMed
    1. Weber JS, Levit LA, Adamson PC, et al. American Society of Clinical Oncology policy statement update: The critical role of phase I trials in cancer research and treatment. J Clin Oncol. 2015;33:278–284. - PMC - PubMed
    1. American Society of Clinical Oncology: ASCO Comment Letter on Proposed Rule and Draft Policy on Clinical Trials Registration and Results Submission, February 2015. http://www.asco.org/sites/new-www.asco.org/files/content-files/blog-rele....
    1. Schwaederle M, Zhao M, Lee JJ, et al. Association of biomarker-based treatment strategies with response rates and progression-free survival in refractory malignant neoplasms: A meta-analysis. JAMA Oncol. [epub ahead of print on June 6, 2016] - PubMed
    1. Ribas A, Hamid O, Daud A, et al. Association of pembrolizumab with tumor response and survival among patients with advanced melanoma. JAMA. 2016;315:1600–1609. - PubMed

LinkOut - more resources